September 11th 2025
Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.
ASCEMBL: Recent Data Updates for Asciminib in CML
Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.
Potential Role of Olverembatinib in CML
The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.
Goals of Treatment for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL)
October 27th 2023Medical expert discusses that when managing relapsed or refractory chronic lymphocytic leukemia, the goals are similar to first-line therapy, and he emphasizes using BCL-2 and BTK inhibitors, guided by factors such as previous therapies, patient preferences, and comorbidities.
Clinical Case Scenario: Managing a Diagnosis of Atrial Fibrillation
October 27th 2023Experts discuss the management of a patient with chronic lymphocytic leukemia who experienced adverse effects such as joint pain and atrial fibrillation while on treatment with ibrutinib, emphasizing the role of cardio-oncology and considering a switch to a second-generation BTK inhibitor for better safety and fewer drug interactions.
Olverembatinib in Patients with Pretreated/Refractory CML
Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.
Treatment Considerations for Ponatinib in Patients With CML
Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.
The Role of Combination Venetoclax and BTKi Therapy for Firstline Treatment of CLL
October 20th 2023Ricardo Parrondo, MD, discusses the potential of combining BTK and BCL2 inhibitors in chronic lymphocytic leukemia treatment, emphasizing their synergistic effect and cautioning against use in frail patients or those with cardiovascular comorbidities, while Pooja Advani, MBBS, MD, stresses the importance of medical history and risk stratification, especially regarding cardiovascular adverse effects.
Ponatinib Dose-Ranging Data in Chronic-Phase CML
Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.
Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic
A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.
Influence of BTKi-Related Adverse Event Patterns on Treatment Selection for Patients With CLLTN
October 13th 2023Experts discuss that although first-generation BTK inhibitors such as ibrutinib were groundbreaking for CLL treatment, the field is now shifting toward second-generation options because of their better toxicity profiles. However, the choice between second-generation inhibitors should be personalized, considering individual patient profiles and adverse effects.
Ibrutinib Combo Improves PFS Vs Chlorambucil Combo in CLL Genomic Subgroups
October 6th 2023Patients receiving ibrutinib plus venetoclax for chronic lymphocytic leukemia appear to experience improved overall survival at 46 months compared with those receiving chlorambucil plus obinutuzumab in the phase 3 GLOW study.
Firstline BTKi Monotherapy in Patients With CLL: 4-Year Follow-Up Data from SEQUOIA
October 6th 2023SEQUOIA trial data show significant benefits in progression-free survival for patients with chronic lymphocytic leukemia treated with single-agent zanubrutinib, even without a high-risk 17P mutation; Pooja Advani, MD, MBBS, notes that second-generation BTK inhibitors show lower rates of atrial fibrillation and flutter compared with first-generation ones, suggesting increased cardiac safety.
Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy
Expert insight into the later-line efficacy and tolerability of olverembatinib, a third generation TKI, in ponatinib-resistant, refractory chronic myeloid leukemia populations.
Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML
Considerations for selecting between ponatinib and asciminib as third-line therapies for CML based on factors such as disease burden, mutations, and patient tolerability.
Currently Available Treatment Options for Patients With CLL
September 29th 2023Mayo Clinic experts note that targeted therapies for chronic lymphocytic leukemia are generally superior to chemoimmunotherapy, with treatment choices tailored to patient comorbidities and preferences, and noting that real-world data mostly aligns with clinical trials.
Clinical Case Scenario: A 55-Year-Old Patient With Chronic Lymphocytic Leukemia (CLL)
September 29th 2023In a virtual discussion hosted by Asher A. Chanan-Khan, MD, MBBS, experts from Mayo Clinic discuss treatment strategies for chronic lymphocytic leukemia, including the role of cardio-oncology and various therapeutic approaches.
Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study
A review of promising results from the ASCEMBL study, highlighting asciminib's superior efficacy, well-tolerated profile, and potential impact on chronic myeloid leukemia treatment options.
Cross Q&A: Managing Cardiovascular Risks in CML Treatment
A panel of experts discusses the challenges and considerations surrounding cardiovascular risks associated with ponatinib treatment for chronic myeloid leukemia, emphasizing the need for multidisciplinary collaboration and individualized treatment strategies.